RESUMEN
PURPOSE: To examine the clinical efficacy of a chlorhexidine gargle combined with recombinant bovine basic fibroblast growth factor (rb-bFGF) gel in the treatment of recurrent oral ulcers and its effects on inflammatory factors, immune function, and recurrence rate. MATERIALS AND METHODS: Ninety-six patients with recurrent oral ulcers were randomly assigned to two groups: experimental (treatment with chlorhexidine gargle plus rb-bFGF gel) and control (treatment with chlorhexidine gargle alone) (n = 48 cases). The therapeutic efficacy, clinical improvement of symptoms, and recurrence rate within 3 months were compared between the two groups. Serum inflammatory factor and immune factor levels of patients in the two groups were measured before and after treatment. RESULTS: A statistically significantly higher total effective rate was found in patients of the experimental group (95.83%) versus the control group (81.25%) (p < 0.05). The time to onset of pain relief was shortened, the duration of pain relief was prolonged, and VAS scores for pain level were lower in the experimental than the control group (p < 0.05). Among patients in the experimental group, the number of oral ulcers and ulcer area decreased, and faster onset of pain relief and time until normal eating improved in comparison to the control group (p < 0.05). Reduced levels of IL-2, IL-6, IL-8, and TNF-α were observed in the experimental vs the control group (p < 0.05). Elevated levels of CD3+, CD4+, and NKT and reduced levels of CD8+ were found in the experimental group compared to the control group (p < 0.05). The ulcer recurrence rate of patients in the experimental group (8.33%) was notably lower in comparison to the control group (29.17%). CONCLUSION: Chlorhexidine gargle plus rb-bFGF gel can improve the clinical outcome of patients with recurrent oral ulcers. It can reduce the levels of inflammatory factors, improve immune function, and reduce the recurrence rate.
Asunto(s)
Clorhexidina , Úlceras Bucales , Humanos , Animales , Bovinos , Clorhexidina/uso terapéutico , Factor 2 de Crecimiento de Fibroblastos , Úlcera , Antisépticos Bucales , Resultado del Tratamiento , DolorRESUMEN
Objective:To explore the clinical effect of compound glycyrrhizin tablets combined with recombinant bovine basic fibroblast growth factor gel in the treatment of facial hormone-dependent dermatitis. Methods:Totally 108 patients with facial hormone-dependent dermatitis were selected randomly and divided into the control group(n = 54) and the treatment group(n =54). The control group was treated with desloratadine and 0.1% tacrolimus ointment;and the treatment group was treated with compound glycyrrhizin tablets combined with recombinant bovine basic fibroblast growth factor gel additionally on the basis of control group. The clinical efficacy of the two groups was evaluated,and the improvement of symptoms and objective signs before and after the treatment was compared. The adverse reactions were recorded as well. Results:The total effective rate of the treatment group after one-month and two-month treatment was 75.93% and 90.74%, respectively, which were both higher than those of the control group(P < 0.05). The scores of symptoms and objective signs and the total scores of disease of the treatment group after one-month and two-month treatment and two-month follow-up were all lower than those of the control group, and the differences were statistically significant(P <0.05). The disappearance time of objective signs and the incidence of facial adverse reactions were both lower than those of the control group,and the differences were statistically significant(P < 0.05),however, the incidence of dry mouth in the treatment group was higher than that in the control group(P < 0.05). Conclusion:Compound glycyrrhizin tablets combined with recombinant bovine basic fibroblast growth factor gel has better clinical effect for the therapy of facial hormone-dependent dermatitis,which can improve the symptoms significantly with high application security.